TN2010000212A1 - Inhibitors of human immunodeficiency virus replication - Google Patents

Inhibitors of human immunodeficiency virus replication

Info

Publication number: TN2010000212A1
Authority: TN; Tunisia
Prior art keywords: inhibitors; immunodeficiency virus; human immunodeficiency; virus replication; replication
Prior art date: 2007-11-16

Application number

TN2010000212A

Other languages

English (en)

Original Assignee

Gilead Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-16

Filing date

2010-05-14

Publication date

2011-11-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40638275&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2010000212(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-05-14 Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc

2011-11-11 Publication of TN2010000212A1 publication Critical patent/TN2010000212A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Quinoline Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TN2010000212A 2007-11-16 2010-05-14 Inhibitors of human immunodeficiency virus replication TN2010000212A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US98868607P	2007-11-16	2007-11-16
PCT/CA2008/001611 WO2009062285A1 (fr)	2007-11-16	2008-09-11	Inhibiteurs de la réplication du virus de l'immunodéficience humaine

Publications (1)

Publication Number	Publication Date
TN2010000212A1 true TN2010000212A1 (en)	2011-11-11

Family

ID=40638275

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2010000212A TN2010000212A1 (en)	2007-11-16	2010-05-14	Inhibitors of human immunodeficiency virus replication

Country Status (26)

Country	Link
US (3)	US8354429B2 (fr)
EP (2)	EP2757096A1 (fr)
JP (2)	JP5285709B2 (fr)
KR (1)	KR20100097156A (fr)
CN (1)	CN101918365B (fr)
AR (1)	AR069335A1 (fr)
AU (1)	AU2008323558C1 (fr)
BR (1)	BRPI0820307A2 (fr)
CA (1)	CA2707418C (fr)
CL (1)	CL2008003406A1 (fr)
CO (1)	CO6280400A2 (fr)
EA (2)	EA019259B1 (fr)
EC (1)	ECSP10010206A (fr)
HK (1)	HK1199731A1 (fr)
IL (1)	IL205581A (fr)
MA (1)	MA31906B1 (fr)
MX (1)	MX2010005334A (fr)
NZ (1)	NZ585226A (fr)
PE (3)	PE20130008A1 (fr)
SG (1)	SG185995A1 (fr)
TN (1)	TN2010000212A1 (fr)
TW (1)	TWI437992B (fr)
UA (1)	UA100250C2 (fr)
UY (1)	UY31472A1 (fr)
WO (1)	WO2009062285A1 (fr)
ZA (1)	ZA201003283B (fr)

Families Citing this family (197)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE541841T1 (de) *	2007-11-15	2012-02-15	Boehringer Ingelheim Int	Inhibitoren der replikation des human immunodeficiency virus
KR20100097156A (ko) *	2007-11-16	2010-09-02	베링거 인겔하임 인터내셔날 게엠베하	사람 면역결핍 바이러스 복제의 억제제
UY32306A (es)	2008-12-09	2010-07-30	Gilead Sciences Inc	Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
GB0908394D0 (en)	2009-05-15	2009-06-24	Univ Leuven Kath	Novel viral replication inhibitors
US8338441B2 (en) *	2009-05-15	2012-12-25	Gilead Sciences, Inc.	Inhibitors of human immunodeficiency virus replication
GB0913636D0 (en)	2009-08-05	2009-09-16	Univ Leuven Kath	Novel viral replication inhibitors
NZ604716A (en) *	2010-07-02	2014-12-24	Gilead Sciences Inc	2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
US9102614B2 (en) *	2010-07-02	2015-08-11	Gilead Sciences, Inc.	Naphth-2-ylacetic acid derivatives to treat AIDS
US8633200B2 (en)	2010-09-08	2014-01-21	Bristol-Myers Squibb Company	Inhibitors of human immunodeficiency virus replication
CA2817165A1 (fr)	2010-11-15	2012-05-24	Patrick Chaltin	Nouveaux composes antiviraux
EP2694160A1 (fr)	2011-04-04	2014-02-12	Gilead Sciences, Inc.	Formes à l'état solide d'un inhibiteur du vih
JP2014511859A (ja) *	2011-04-04	2014-05-19	ギリアードサイエンシーズ，インコーポレイテッド	Ｈｉｖインテグラーゼ阻害剤の調製のためのプロセス
EP2508511A1 (fr)	2011-04-07	2012-10-10	Laboratoire Biodim	Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
ES2742261T3 (es) *	2011-04-15	2020-02-13	Hivih	Inhibidores de la replicación viral, su proceso de preparación y sus usos terapéuticos
US9006229B2 (en)	2011-04-21	2015-04-14	Gilead Sciences, Inc.	Benzothiazole compounds and their pharmaceutical use
CA2840095A1 (fr)	2011-07-06	2013-01-10	Gilead Sciences, Inc.	Composes pour traiter le vih
US8609653B2 (en)	2011-07-15	2013-12-17	Glaxosmithkline Llc	Azaindole compounds and methods for treating HIV
US8791108B2 (en)	2011-08-18	2014-07-29	Bristol-Myers Squibb Company	Inhibitors of human immunodeficiency virus replication
EP2757887B1 (fr) *	2011-09-22	2017-04-26	VIIV Healthcare UK Limited	Composés pyrrolopyridinones et méthodes de traitement du vih
EP2772480B2 (fr)	2011-10-25	2020-12-09	Shionogi & Co., Ltd.	Inhibiteur de la réplication du vih
HUE046795T2 (hu)	2011-11-15	2020-03-30	St Pharm Co Ltd	Új vírusellenes pirrolopiridin származékok és eljárás azok elõállítására
US9376392B2 (en)	2012-01-04	2016-06-28	Gilead Sciences, Inc.	2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
WO2013103738A1 (fr) *	2012-01-04	2013-07-11	Gilead Sciences, Inc.	Dérivés d'acide naphtalène acétique contre l'infection par le vih
US8629276B2 (en)	2012-02-15	2014-01-14	Bristol-Myers Squibb Company	Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) *	2012-03-05	2015-05-19	Bristol-Myers Squibb Company	Inhibitors of human immunodeficiency virus replication
US9006235B2 (en)	2012-03-06	2015-04-14	Bristol-Myers Squibb Company	Inhibitors of human immunodeficiency virus replication
RU2014115227A (ru)	2012-04-20	2015-10-27	Джилид Сайэнс, Инк.	Производные бензотиазол-6-ил уксусной кислоты и их примение для лечения вич-инфекции
EP2844231A1 (fr) *	2012-05-03	2015-03-11	Cipla Limited	Composition antirétrovirale
WO2014009794A1 (fr) *	2012-07-12	2014-01-16	Viiv Healthcare Uk Limited	Composés et procédés de traitement du vih
US8906929B2 (en)	2012-08-16	2014-12-09	Bristol-Myers Squibb Company	Inhibitors of human immunodeficiency virus replication
US20140094609A1 (en) *	2012-10-03	2014-04-03	Gilead Sciences, Inc.	Process for the preparation of an hiv integrase inhibitor
US20140094485A1 (en)	2012-10-03	2014-04-03	Gilead Sciences, Inc.	Solid state forms of hiv inhibitor
EP2716632A1 (fr)	2012-10-05	2014-04-09	Laboratoire Biodim	Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
EP2716639A1 (fr)	2012-10-05	2014-04-09	Laboratoire Biodim	Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
EP2719685A1 (fr)	2012-10-11	2014-04-16	Laboratoire Biodim	Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
PT3067358T (pt)	2012-12-21	2019-11-18	Gilead Sciences Inc	Compostos carbamoílpiridona policíclicos e sua utilização farmacêutica
TW201443037A (zh)	2013-01-09	2014-11-16	Gilead Sciences Inc	治療用化合物
AU2014205317B2 (en)	2013-01-09	2016-11-24	Gilead Sciences, Inc.	5-membered heteroaryls and their use as antiviral agents
AU2014205315B2 (en)	2013-01-09	2016-11-17	Gilead Sciences, Inc.	Therapeutic compounds for the treatment of viral infections
TW201441197A (zh)	2013-01-31	2014-11-01	Shionogi & Co	Ｈｉｖ複製抑制劑
TWI706945B (zh)	2013-03-01	2020-10-11	美商基利科學股份有限公司	供治療反轉錄病毒科病毒感染之治療性化合物
JP2016516692A (ja)	2013-03-13	2016-06-09	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	ヒト免疫不全ウイルス複製の阻害剤
US9580431B2 (en)	2013-03-13	2017-02-28	VIIV Healthcare UK (No.5) Limited	Inhibitors of human immunodeficiency virus replication
EP2970273B1 (fr)	2013-03-13	2017-03-01	VIIV Healthcare UK (No.5) Limited	Inhibiteurs de la réplication du virus de l'immunodéficience humaine
WO2014159076A1 (fr)	2013-03-14	2014-10-02	Bristol-Myers Squibb Company	Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP2970274B1 (fr)	2013-03-14	2017-03-01	VIIV Healthcare UK (No.5) Limited	Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3010586A1 (fr)	2013-06-21	2016-04-27	Lupin Limited	Composés hétérocycliques substitués utiles en tant que modulateurs de crac
CA2914415A1 (fr)	2013-06-24	2014-12-31	Lupin Limited	Derives de chromane et de chromene et leur utilisation en tant que modulateurs de crac
EP2821104A1 (fr)	2013-07-05	2015-01-07	Laboratoire Biodim	Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
EP2821082A1 (fr)	2013-07-05	2015-01-07	Laboratoire Biodim	Procédé de production d'un lentivirus inactivé, notamment le VIH, vaccin, kit et procédé d'utilisation
AU2014286993B2 (en)	2013-07-12	2018-10-25	Gilead Sciences, Inc.	Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections
NO2865735T3 (fr)	2013-07-12	2018-07-21
CN103467374A (zh) *	2013-08-30	2013-12-25	江苏弘和药物研发有限公司	一种8-溴-4-羧基喹啉的合成方法
EP3105236B1 (fr)	2014-02-12	2017-10-18	ViiV Healthcare UK (No.5) Limited	Utilisation de macrocycles de benzothiazole comme qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3116879A1 (fr)	2014-02-18	2017-01-18	VIIV Healthcare UK (No.5) Limited	Macrocycles d'imidazopyrimidine utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine
WO2015126743A1 (fr)	2014-02-18	2015-08-27	Bristol-Myers Squibb Company	Macrocycles de pyrazolopyrimidine utilisés en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
US9409922B2 (en)	2014-02-18	2016-08-09	Bristol-Myers Squibb Company	Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
US9273067B2 (en)	2014-02-19	2016-03-01	Bristol-Myers Squibb Company	Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
PT3107913T (pt)	2014-02-19	2018-09-28	Viiv Healthcare Uk No 5 Ltd	Inibidores da replicação do vírus da imunodeficiência humana
EP3116880B1 (fr)	2014-02-20	2018-03-21	VIIV Healthcare UK (No.5) Limited	Macrocycles pyridin-3-yl-acide acétique en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
US9193720B2 (en)	2014-02-20	2015-11-24	Bristol-Myers Squibb Company	Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2015130964A1 (fr)	2014-02-28	2015-09-03	Gilead Sciences, Inc.	Composés thérapeutiques
JP6579549B2 (ja)	2014-05-16	2019-09-25	塩野義製薬株式会社	Ｈｉｖ複製阻害作用を有する３環性複素環誘導体
WO2015179448A1 (fr) *	2014-05-21	2015-11-26	Gilead Sciences, Inc.	Composés thérapeutiques
TW201613936A (en)	2014-06-20	2016-04-16	Gilead Sciences Inc	Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (fr)	2014-06-20	2018-06-23
SG11201700070QA (en)	2014-07-11	2017-02-27	Gilead Sciences Inc	Modulators of toll-like receptors for the treatment of hiv
RU2017103656A (ru)	2014-07-22	2018-08-22	ВАЙВ ХЕЛТКЕР ЮКей ЛИМИТЕД	Производные изоиндолинона, полезные в качестве противовирусных средств
US20160067255A1 (en)	2014-09-04	2016-03-10	Gilead Sciences, Inc.	Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
WO2016044182A1 (fr)	2014-09-16	2016-03-24	Gilead Sciences, Inc.	Formes solides d'un modulateur de récepteurs de type toll
TWI695003B (zh)	2014-12-23	2020-06-01	美商基利科學股份有限公司	多環胺甲醯基吡啶酮化合物及其醫藥用途
TW202237569A (zh)	2014-12-24	2022-10-01	美商基利科學股份有限公司	喹唑啉化合物
AU2015371255B2 (en)	2014-12-24	2018-09-27	Gilead Sciences, Inc.	Fused pyrimidine compounds for the treatment of HIV
EP3237397B1 (fr)	2014-12-24	2018-11-21	Gilead Sciences, Inc.	Composés isoindoline pour le traitement du vih
MY199989A (en)	2015-03-04	2023-12-02	Gilead Sciences Inc	Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
NZ735575A (en)	2015-04-02	2018-11-30	Gilead Sciences Inc	Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
MX2017015256A (es)	2015-05-29	2018-02-19	Shionogi & Co	Derivados triciclicos que contienen nitrogeno que tienen actividad inhibidora de la replicacion del virus de inmunodeficiencia adquirida (vih).
KR20180025928A (ko)	2015-07-06	2018-03-09	비브 헬스케어 유케이 (넘버5) 리미티드	인간 면역결핍 바이러스 복제의 억제제로서 피리딘-3-일 아세트산 유도체
EP3319957A1 (fr)	2015-07-08	2018-05-16	VIIV Healthcare UK (No.5) Limited	Dérivés de l'acide pyridin-3-yl-acétique utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine
CA2991464A1 (fr)	2015-07-09	2017-01-12	VIIV Healthcare UK (No.5) Limited	Derives de l'acide pyridin-3-yl-acetique utilises comme inhibiteurs de la replication du virus de l'immunodeficience humaine
CA2991467A1 (fr)	2015-07-09	2017-01-12	VIIV Healthcare UK (No.5) Limited	Derives de l'acide pyridin-3-yl-acetique utilises comme inhibiteurs de la replication du virus de l'immunodeficience humaine
WO2017011517A1 (fr)	2015-07-16	2017-01-19	Emory University	Bis-amines, compositions et utilisations associées à l'inhibition de cxcr4
JP2018522052A (ja)	2015-08-07	2018-08-09	ヴィーブヘルスケアユーケー（ナンバー５）リミテッド	ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
CN108026113A (zh)	2015-08-10	2018-05-11	Viiv保健英国第五有限公司	作为人免疫缺陷病毒复制的抑制剂的咪唑并吡啶大环类化合物
AR105653A1 (es)	2015-08-11	2017-10-25	VIIV HEALTHCARE UK (Nº 5) LTD	Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
CA2995087A1 (fr)	2015-08-12	2017-02-16	John F. Kadow	Derives tricycliques condenses d'acide 5-(n-aryle tetrahydroisoquinoline-6-yl) pyridin-3-yl acetique comme inhibiteurs de la replication du virus d'immunodeficience humaine
JP2018522913A (ja)	2015-08-12	2018-08-16	ヴィーブヘルスケアユーケー（ナンバー５）リミテッド	ヒト免疫不全ウイルス複製の阻害剤としての５−（ｎ−［６，５］−縮合二環式アリールテトラヒドロイソキノリン−６−イル）ピリジン−３−イル酢酸誘導体
TW201718537A (zh)	2015-08-12	2017-06-01	Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司	做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物
RU2018107928A (ru)	2015-08-20	2019-09-20	ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД	Производные пиридин-3-ил уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека
WO2017035230A1 (fr)	2015-08-26	2017-03-02	Gilead Sciences, Inc.	Modulateurs deutérés du récepteur toll
HK1257270A1 (zh)	2015-09-15	2019-10-18	Gilead Sciences, Inc.	用於治療hiv的toll樣受體(tlr)調節劑
WO2017059120A1 (fr)	2015-09-30	2017-04-06	Gilead Sciences, Inc.	Composés et combinaisons pour le traitement du vih
LT3390441T (lt)	2015-12-15	2021-11-10	Gilead Sciences, Inc.	Žmogaus imunodeficito virusą neutralizuojantys antikūnai
WO2017195112A1 (fr)	2016-05-11	2017-11-16	VIIV Healthcare UK (No.5) Limited	Dérivés d'acide pyridin-3-yle acétique utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3455214A1 (fr)	2016-05-11	2019-03-20	ViiV Healthcare UK (No.5) Limited	Dérivés d'acide pyridin-3-yle acétique utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine
US10407410B2 (en)	2016-05-11	2019-09-10	VIIV Healthcare UK (No.5) Limited	Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3497089B1 (fr)	2016-08-12	2020-07-29	Bayer CropScience Aktiengesellschaft	Procédé pour la préparation de dérivés de 2,3-dihydro-1-benzofurane substitués en position 4 par cyclisation de séls 2-(2-diazonium-6-substitué-phényl)éthanol
KR20250085838A (ko)	2016-08-19	2025-06-12	길리애드 사이언시즈, 인코포레이티드	Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물
WO2018042332A1 (fr)	2016-08-31	2018-03-08	Glaxosmithkline Intellectual Property (No.2) Limited	Combinaisons, utilisations et traitements correspondants
WO2018042331A1 (fr)	2016-08-31	2018-03-08	Glaxosmithkline Intellectual Property (No.2) Limited	Combinaisons, utilisations et traitements correspondants
AU2017318601B2 (en)	2016-09-02	2020-09-03	Gilead Sciences, Inc.	Toll like receptor modulator compounds
ES2826748T3 (es)	2016-09-02	2021-05-19	Gilead Sciences Inc	Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
WO2018051250A1 (fr)	2016-09-14	2018-03-22	Viiv Healthcare Company	Combinaison comprenant du ténofovir alafénamide, du bictégravir et du 3tc
WO2018064080A1 (fr)	2016-09-28	2018-04-05	Gilead Sciences, Inc.	Dérivés d'acide benzothiazol-6-yl-acétique et leur utilisation pour le traitement d'une infection par le vih
ES2881949T3 (es)	2016-10-27	2021-11-30	Gilead Sciences Inc	Forma cristalina de base libre de darunavir
US20200016136A1 (en)	2017-01-03	2020-01-16	Viiv Healthcare Uk (No. 5) Limited	Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
UY37555A (es)	2017-01-03	2018-08-31	Viiv Healthcare Uk No 5 Ltd	Derivados de ácido piridin-3-il-acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
WO2018138050A1 (fr)	2017-01-26	2018-08-02	Bayer Aktiengesellschaft	Dérivés hétérocycliques bicycliques condensés utilisés comme pesticides
TWI714820B (zh)	2017-01-31	2021-01-01	美商基利科學股份有限公司	替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型
JOP20180009A1 (ar)	2017-02-06	2019-01-30	Gilead Sciences Inc	مركبات مثبط فيروس hiv
AU2017405244C9 (en) *	2017-03-24	2021-03-04	St Pharm Co., Ltd.	Novel pyrrolopyridine derivative, method for producing same, and use thereof
EP3642229A1 (fr)	2017-06-21	2020-04-29	Gilead Sciences, Inc.	Anticorps multispécifiques ciblant gp120 et cd3 du vih
US12011506B2 (en)	2017-06-30	2024-06-18	Viiv Healthcare Company	Combination and uses and treatments thereof
PL3661937T3 (pl)	2017-08-01	2021-12-20	Gilead Sciences, Inc.	Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych
TWI687415B (zh)	2017-08-17	2020-03-11	美商基利科學股份有限公司	Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es)	2017-08-17	2019-10-23	Gilead Sciences Inc	Formas de sal de colina de un inhibidor de la cápside del vih
CN111051305A (zh)	2017-08-22	2020-04-21	吉利德科学公司	治疗性杂环化合物
JOP20180092A1 (ar)	2017-10-13	2019-04-13	Gilead Sciences Inc	مثبطات hiv بروتياز
EP3700573A1 (fr)	2017-10-24	2020-09-02	Gilead Sciences, Inc.	Méthodes de traitement de patients co-infectés par un virus et la tuberculose
AU2018392213B2 (en)	2017-12-20	2021-03-04	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
KR102492115B1 (ko)	2017-12-20	2023-01-27	인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이.	Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 2'3' 사이클릭 다이뉴클레오티드
CA3087359C (fr)	2018-01-19	2023-07-25	Gilead Sciences, Inc.	Metabolites du bictegravir
KR102587510B1 (ko)	2018-02-15	2023-10-11	길리애드 사이언시즈, 인코포레이티드	피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도
CN112055712B (zh)	2018-02-16	2023-07-14	吉利德科学公司	用于制备可用于治疗逆转录病毒科病毒感染的治疗性化合物的方法和中间体
TW202005654A (zh)	2018-04-06	2020-02-01	捷克科學院有機化學與生物化學研究所	２，２，─環二核苷酸
TWI818007B (zh)	2018-04-06	2023-10-11	捷克科學院有機化學與生物化學研究所	2'3'-環二核苷酸
TWI833744B (zh)	2018-04-06	2024-03-01	捷克科學院有機化學與生物化學研究所	3'3'-環二核苷酸
WO2019211799A1 (fr)	2018-05-03	2019-11-07	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	Analogue de dinucléotide 2'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle
WO2019244066A2 (fr)	2018-06-19	2019-12-26	VIIV Healthcare UK (No.5) Limited	Dérivés d'acide pyridin-3-yl-acétique en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
WO2020003093A1 (fr)	2018-06-25	2020-01-02	VIIV Healthcare UK (No.5) Limited	Dérivés d'acide pyridin-3-yl-acétique en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
CR20200653A (es)	2018-07-03	2021-02-11	Gilead Sciences Inc	Anticuerpos que se dirigen al gp120 de vih y métodos de uso
AU2019297428C1 (en)	2018-07-06	2023-03-23	Gilead Sciences, Inc.	Therapeutic heterocyclic compounds
US11098027B2 (en)	2018-07-06	2021-08-24	Gilead Sciences, Inc.	Therapeutic heterocyclic compounds
CA3216031A1 (fr)	2018-07-16	2020-01-23	Gilead Sciences, Inc.	Inhibiteurs de capsides pour le traitement du vih
TWI829205B (zh)	2018-07-30	2024-01-11	美商基利科學股份有限公司	抗hiv化合物
KR20250161656A (ko)	2018-09-19	2025-11-17	길리애드 사이언시즈, 인코포레이티드	Hiv 예방용 인테그라제 억제제
US11179397B2 (en)	2018-10-03	2021-11-23	Gilead Sciences, Inc.	Imidazopyrimidine derivatives
EP3873608A1 (fr)	2018-10-31	2021-09-08	Gilead Sciences, Inc.	Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1
AU2019372046B2 (en)	2018-10-31	2022-05-26	Gilead Sciences, Inc.	Substituted 6-azabenzimidazole compounds as HPK1 inhibitors
WO2020176505A1 (fr)	2019-02-25	2020-09-03	Gilead Sciences, Inc.	Agonistes de protéine kinase c
WO2020176510A1 (fr)	2019-02-25	2020-09-03	Gilead Sciences, Inc.	Agonistes de protéine kinase c
JP7350872B2 (ja)	2019-03-07	2023-09-26	インスティチュートオブオーガニックケミストリーアンドバイオケミストリーエーエスシーアール，ヴイ．ヴイ．アイ．	３’３’－環状ジヌクレオチドおよびそのプロドラッグ
EP3935065A1 (fr)	2019-03-07	2022-01-12	Institute of Organic Chemistry and Biochemistry ASCR, V.V.I.	Analogue du dinucléotide 3'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle utilisé en tant que modulateur de sting
US12318403B2 (en)	2019-03-07	2025-06-03	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	2′3′-cyclic dinucleotides and prodrugs thereof
HUE059677T2 (hu)	2019-03-22	2022-12-28	Gilead Sciences Inc	Áthidalt triciklusos karbamoilpiridon-vegyületek és ezek gyógyszerészeti alkalmazása
US20200347036A1 (en)	2019-04-17	2020-11-05	Gilead Sciences, Inc.	Solid forms of an hiv protease inhibitor
TWI751517B (zh)	2019-04-17	2022-01-01	美商基利科學股份有限公司	類鐸受體調節劑之固體形式
TW202104210A (zh)	2019-04-17	2021-02-01	美商基利科學股份有限公司	Hiv蛋白酶抑制劑
TWI751516B (zh)	2019-04-17	2022-01-01	美商基利科學股份有限公司	類鐸受體調節劑之固體形式
TW202231277A (zh)	2019-05-21	2022-08-16	美商基利科學股份有限公司	鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
WO2020237025A1 (fr)	2019-05-23	2020-11-26	Gilead Sciences, Inc.	Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1
RU2717101C1 (ru)	2019-06-03	2020-03-18	Андрей Александрович Иващенко	Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
WO2020255038A1 (fr)	2019-06-18	2020-12-24	Janssen Sciences Ireland Unlimited Company	Association de vaccins contre le virus de l'hépatite b (vhb) et de dérivés de pyridopyrimidine
MX2021015452A (es)	2019-06-25	2022-02-11	Gilead Sciences Inc	Proteinas de fusion flt3l-fc y metodos de uso.
JP7454645B2 (ja)	2019-07-16	2024-03-22	ギリアードサイエンシーズ，インコーポレイテッド	Ｈｉｖワクチン並びにその作製方法及び使用方法
WO2021011891A1 (fr)	2019-07-18	2021-01-21	Gilead Sciences, Inc.	Formulations à action prolongée de ténofovir alafénamide
WO2021034804A1 (fr)	2019-08-19	2021-02-25	Gilead Sciences, Inc.	Formulations pharmaceutiques de ténofovir alafénamide
CA3157275A1 (fr)	2019-11-26	2021-06-03	Elena BEKERMAN	Inhibiteurs de capside pour la prevention du vih
IL294032A (en)	2019-12-24	2022-08-01	Carna Biosciences Inc	Compounds that regulate diacylglycerol kinase
PE20221569A1 (es)	2020-02-24	2022-10-06	Gilead Sciences Inc	Compuestos tetraciclicos para el tratamiento de infecciones por vih
AU2021237718B2 (en)	2020-03-20	2023-09-21	Gilead Sciences, Inc.	Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
EP4153181A1 (fr)	2020-05-21	2023-03-29	Gilead Sciences, Inc.	Compositions pharmaceutiques contenant du bictégravir
CN115996925A (zh)	2020-06-25	2023-04-21	吉利德科学公司	用于治疗hiv的衣壳抑制剂
PE20230779A1 (es)	2020-08-07	2023-05-09	Gilead Sciences Inc	Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico
US12421235B2 (en)	2020-09-30	2025-09-23	Gilead Sciences, Inc.	Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202406932A (zh)	2020-10-22	2024-02-16	美商基利科學股份有限公司	介白素2-Fc融合蛋白及使用方法
SI4244396T1 (sl)	2020-11-11	2025-10-30	Gilead Sciences, Inc.	Postopki za prepoznavanje pacientov s hiv, ki so občutljivi na terapijo s protitelesi, usmerjenimi proti vezavnemu mestu cd4 od gp120
TW202408533A (zh)	2021-01-19	2024-03-01	美商基利科學股份有限公司	經取代之吡啶并三𠯤化合物及其用途
US20220389394A1 (en)	2021-05-18	2022-12-08	Gilead Sciences, Inc.	METHODS OF USING FLT3L-Fc FUSION PROTEINS
CN117355531A (zh)	2021-06-23	2024-01-05	吉利德科学公司	二酰基甘油激酶调节化合物
EP4359413A1 (fr)	2021-06-23	2024-05-01	Gilead Sciences, Inc.	Composés de modulation de la diacylglycérol kinase
CN117377671A (zh)	2021-06-23	2024-01-09	吉利德科学公司	二酰基甘油激酶调节化合物
CA3220923A1 (fr)	2021-06-23	2022-12-29	Gilead Sciences, Inc.	Composes de modulation de la diacylglycerol kinase
FI4440702T3 (fi)	2021-12-03	2025-08-08	Gilead Sciences Inc	Terapeuttisia yhdisteitä hiv-virusinfektiota varten
TW202342447A (zh)	2021-12-03	2023-11-01	美商基利科學股份有限公司	用於ｈｉｖ病毒感染之治療性化合物
US12084467B2 (en)	2021-12-03	2024-09-10	Gilead Sciences, Inc.	Therapeutic compounds for HIV virus infection
TWI843506B (zh)	2022-04-06	2024-05-21	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途
US20240034724A1 (en)	2022-07-01	2024-02-01	Gilead Sciences, Inc.	Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
CA3259040A1 (fr)	2022-07-12	2024-01-18	Gilead Sciences, Inc.	Polypeptides immunogènes du vih et vaccins et utilisations de ceux-ci
JP2025527677A (ja)	2022-08-26	2025-08-22	ギリアードサイエンシーズ，インコーポレイテッド	広域中和抗体のための投与及びスケジューリングレジメン
US20240226130A1 (en)	2022-10-04	2024-07-11	Gilead Sciences, Inc.	4'-thionucleoside analogues and their pharmaceutical use
WO2024220624A1 (fr)	2023-04-19	2024-10-24	Gilead Sciences, Inc.	Schéma posologique d'inhibiteur de capside
AU2024283382A1 (en)	2023-05-31	2025-11-13	Gilead Sciences, Inc.	Anti-hiv compounds
US20250042926A1 (en)	2023-05-31	2025-02-06	Gilead Sciences, Inc.	Therapeutic compounds for hiv
AU2024281548A1 (en)	2023-05-31	2025-11-13	Gilead Sciences, Inc.	Solid forms of compounds useful in the treatment of hiv
WO2025029247A1 (fr)	2023-07-28	2025-02-06	Gilead Sciences, Inc.	Régime hebdomadaire de lénacapavir pour le traitement et la prévention du vih
WO2025042394A1 (fr)	2023-08-23	2025-02-27	Gilead Sciences, Inc.	Schéma posologique d'un inhibiteur de capside du vih
WO2025076542A1 (fr)	2023-10-05	2025-04-10	Jones R Brad	Atovaquone comme inducteur de ros destiné à être utilisé dans l'élimination de lymphocytes t infectés par le vih
WO2025080863A1 (fr)	2023-10-11	2025-04-17	Gilead Sciences, Inc.	Composés de carbamoylpyridone tricycliques pontés et leurs utilisations
US20250120989A1 (en)	2023-10-11	2025-04-17	Gilead Sciences, Inc.	Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202530226A (zh)	2023-10-11	2025-08-01	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2025137245A1 (fr)	2023-12-22	2025-06-26	Gilead Sciences, Inc.	Formes solides d'inhibiteurs de l'intégrase du vih
WO2025184452A1 (fr)	2024-03-01	2025-09-04	Gilead Sciences, Inc.	Formes solides d'inhibiteurs de l'intégrase du vih
US20250296932A1 (en)	2024-03-01	2025-09-25	Gilead Sciences, Inc.	Pharmaceutical compositions comprising hiv integrase inhibitors
WO2025184609A1 (fr)	2024-03-01	2025-09-04	Gilead Sciences, Inc.	Composés antiviraux
US20250326779A1 (en)	2024-04-03	2025-10-23	Gilead Sciences, Inc.	Anti-hiv compounds
WO2025260028A1 (fr)	2024-06-14	2025-12-18	Gilead Sciences, Inc.	Compositions pharmaceutiques comprenant des inhibiteurs de l'intégrase du vih

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6463518A (en)	1987-09-02	1989-03-09	Otsuka Pharma Co Ltd	Antiarrhythmic agent
EP0403535A1 (fr)	1988-03-01	1990-12-27	The Upjohn Company	Coumarines permettant d'inhiber la transcriptase inverse chez les etres humains
JPH03227923A (ja)	1990-01-30	1991-10-08	Sawai Seiyaku Kk	ひと免疫不全ウイルス疾患処置剤
GB9005518D0 (en)	1990-03-12	1990-05-09	Wellcome Found	Heterocyclic compounds
WO1993004047A1 (fr) *	1991-08-16	1993-03-04	Merck & Co., Inc.	Derives de quinazoline utilises comme inhibiteurs de transcriptase inverse d'hiv
DE4208304A1 (de)	1992-03-16	1993-09-23	Merck Patent Gmbh	2-oxochinolinderivate
DE69315920T2 (de)	1992-09-04	1998-06-10	Takeda Chemical Industries Ltd	Kondensierte heterozyklische Verbindungen, deren Herstellung und Verwendung
IL108459A0 (en)	1993-02-05	1994-04-12	Opjohn Company	4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses
DE19528418A1 (de)	1995-08-02	1997-02-06	Merck Patent Gmbh	Endothelin-Rezeptor-Antagonisten
US6069151A (en)	1996-11-06	2000-05-30	Darwin Discovery, Ltd.	Quinolines and their therapeutic use
US6018049A (en)	1996-12-26	2000-01-25	Shionogi & Co., Ltd.	Process for the preparation of carbamoylated imidazole derivatives
FR2761687B1 (fr) *	1997-04-08	2000-09-15	Centre Nat Rech Scient	Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
FR2772761B1 (fr)	1997-12-23	2000-05-26	Lipha	Nouveaux derives de n-phenylamide et n-pyridylamide, leur procede de preparation et compositions pharmaceutiques les contenant
US6307087B1 (en)	1998-07-10	2001-10-23	Massachusetts Institute Of Technology	Ligands for metals and improved metal-catalyzed processes based thereon
US6395916B1 (en)	1998-07-10	2002-05-28	Massachusetts Institute Of Technology	Ligands for metals and improved metal-catalyzed processes based thereon
JP2002531549A (ja)	1998-12-04	2002-09-24	ブリストル−マイヤーズスクイブカンパニー	カリウムチャネル・モジュレーターとしての３−置換−４−アリールキノリン−２−オン誘導体
EP1255741A2 (fr)	2000-02-01	2002-11-13	Cor Therapeutics, Inc.	2- 1H]-QUINOLONE ET 2- 1H]-QUINOXALONE INHIBITEURS DU FACTEUR Xa
FR2819507B1 (fr) *	2001-01-17	2007-09-28	Inst Rech Developpement Ird	Quinoleines substituees pour le traitement de co-infections a protozoaires et a retrovirus
CA2446324A1 (fr)	2001-05-21	2002-11-28	F. Hoffmann-La Roche Ag	Derives de la quinoleine utilises comme ligands pour le recepteur y de neuropeptide
CN1564683A (zh)	2001-10-11	2005-01-12	爱尔康公司	抗炎类固醇和muc－1促分泌素结合治疗干眼病的方法
DE10155076A1 (de)	2001-11-09	2003-05-22	Merck Patent Gmbh	Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
FR2839646B1 (fr)	2002-05-17	2008-04-11	Bioalliance Pharma	Utilisation de derives de quinoleine a effet anti-integrase et ses applications
JP3908248B2 (ja) *	2002-08-13	2007-04-25	塩野義製薬株式会社	Ｈｉｖインテグラーゼ阻害活性を有するヘテロ環化合物
SI1564210T1 (sl)	2002-11-20	2010-01-29	Japan Tobacco Inc	4-oksokinolinske spojine in njihova uporaba kot inhibitorji HIV integraze
US7642277B2 (en)	2002-12-04	2010-01-05	Boehringer Ingelheim International Gmbh	Non-nucleoside reverse transcriptase inhibitors
SV2005001973A (es)	2003-12-12	2005-11-04	Wyeth Corp	Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500)
US20060094755A1 (en) *	2004-10-28	2006-05-04	Bioflexis, Llc	Novel quinoline-based metal chelators as antiviral agents
EP1866313A1 (fr)	2005-03-31	2007-12-19	Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A.	Inhibiteurs de l`integrase du vih
MX302718B (es)	2005-04-28	2012-08-27	Smithkline Beecham Corp	Derivado de carbamoilpiridona policiclico que tiene actividad inhibidora de la integrasa de hiv.
JP2008542352A (ja)	2005-06-01	2008-11-27	ビオアリアンスファルマ	キノリン化合物及び他のｈｉｖ感染治療薬を含む相乗作用のコンビネーション
JP5094725B2 (ja)	2005-10-04	2012-12-12	イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ	Ｈｉｖインテグラーゼ阻害剤
EA200801144A1 (ru)	2005-10-27	2008-10-30	Сионоги Энд Ко., Лтд.	Полициклическое карбамоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич
US7939545B2 (en) *	2006-05-16	2011-05-10	Boehringer Ingelheim International Gmbh	Inhibitors of human immunodeficiency virus replication
ATE541841T1 (de)	2007-11-15	2012-02-15	Boehringer Ingelheim Int	Inhibitoren der replikation des human immunodeficiency virus
KR20100097156A (ko) *	2007-11-16	2010-09-02	베링거 인겔하임 인터내셔날 게엠베하	사람 면역결핍 바이러스 복제의 억제제
EP2694160A1 (fr)	2011-04-04	2014-02-12	Gilead Sciences, Inc.	Formes à l'état solide d'un inhibiteur du vih
JP2014511859A (ja)	2011-04-04	2014-05-19	ギリアードサイエンシーズ，インコーポレイテッド	Ｈｉｖインテグラーゼ阻害剤の調製のためのプロセス

2008
- 2008-09-11 KR KR1020107013072A patent/KR20100097156A/ko not_active Ceased
- 2008-09-11 UA UAA201007141 patent/UA100250C2/uk unknown
- 2008-09-11 MX MX2010005334A patent/MX2010005334A/es active IP Right Grant
- 2008-09-11 CN CN2008801247428A patent/CN101918365B/zh not_active Expired - Fee Related
- 2008-09-11 SG SG2012083531A patent/SG185995A1/en unknown
- 2008-09-11 AU AU2008323558A patent/AU2008323558C1/en not_active Ceased
- 2008-09-11 EA EA201000777A patent/EA019259B1/ru not_active IP Right Cessation
- 2008-09-11 NZ NZ585226A patent/NZ585226A/xx not_active IP Right Cessation
- 2008-09-11 BR BRPI0820307A patent/BRPI0820307A2/pt not_active IP Right Cessation
- 2008-09-11 EA EA201200631A patent/EA201200631A1/ru unknown
- 2008-09-11 EP EP13197322.4A patent/EP2757096A1/fr not_active Withdrawn
- 2008-09-11 JP JP2010533392A patent/JP5285709B2/ja active Active
- 2008-09-11 US US12/742,997 patent/US8354429B2/en active Active
- 2008-09-11 EP EP08800314.0A patent/EP2220046B1/fr active Active
- 2008-09-11 WO PCT/CA2008/001611 patent/WO2009062285A1/fr not_active Ceased
- 2008-09-11 CA CA2707418A patent/CA2707418C/fr not_active Expired - Fee Related
- 2008-11-14 PE PE2012001160A patent/PE20130008A1/es not_active Application Discontinuation
- 2008-11-14 CL CL2008003406A patent/CL2008003406A1/es unknown
- 2008-11-14 TW TW097144269A patent/TWI437992B/zh not_active IP Right Cessation
- 2008-11-14 PE PE2008001933A patent/PE20091000A1/es not_active Application Discontinuation
- 2008-11-14 AR ARP080104990A patent/AR069335A1/es not_active Application Discontinuation
- 2008-11-14 PE PE2012001161A patent/PE20130009A1/es not_active Application Discontinuation
- 2008-11-14 UY UY31472A patent/UY31472A1/es not_active Application Discontinuation
2010
- 2010-05-06 IL IL205581A patent/IL205581A/en not_active IP Right Cessation
- 2010-05-10 ZA ZA2010/03283A patent/ZA201003283B/en unknown
- 2010-05-14 TN TN2010000212A patent/TN2010000212A1/fr unknown
- 2010-05-14 CO CO10058231A patent/CO6280400A2/es active IP Right Grant
- 2010-05-27 EC EC2010010206A patent/ECSP10010206A/es unknown
- 2010-06-09 MA MA32901A patent/MA31906B1/fr unknown
2012
- 2012-11-21 US US13/683,761 patent/US8710230B2/en active Active
2013
- 2013-05-31 JP JP2013115884A patent/JP2013241410A/ja not_active Withdrawn
2014
- 2014-02-28 US US14/194,520 patent/US20140296228A1/en not_active Abandoned
2015
- 2015-01-08 HK HK15100191.0A patent/HK1199731A1/en unknown

Also Published As

Publication number	Publication date
BRPI0820307A2 (pt)	2019-09-24
CN101918365B (zh)	2013-10-09
WO2009062285A1 (fr)	2009-05-22
EP2757096A1 (fr)	2014-07-23
CL2008003406A1 (es)	2010-01-11
EA201000777A1 (ru)	2010-12-30
EP2220046A1 (fr)	2010-08-25
IL205581A0 (en)	2010-11-30
EP2757096A9 (fr)	2014-11-26
AU2008323558C1 (en)	2014-05-01
MX2010005334A (es)	2010-05-27
HK1147096A1 (en)	2011-07-29
NZ585226A (en)	2012-08-31
US20130197231A1 (en)	2013-08-01
KR20100097156A (ko)	2010-09-02
US20100311735A1 (en)	2010-12-09
PE20130009A1 (es)	2013-02-05
CA2707418A1 (fr)	2009-05-22
ECSP10010206A (es)	2010-06-29
AR069335A1 (es)	2010-01-13
SG185995A1 (en)	2012-12-28
UA100250C2 (uk)	2012-12-10
CN101918365A (zh)	2010-12-15
US8354429B2 (en)	2013-01-15
EA201200631A1 (ru)	2012-11-30
CO6280400A2 (es)	2011-05-20
JP5285709B2 (ja)	2013-09-11
JP2013241410A (ja)	2013-12-05
TW200932227A (en)	2009-08-01
EP2220046B1 (fr)	2014-06-18
JP2011503116A (ja)	2011-01-27
TWI437992B (zh)	2014-05-21
MA31906B1 (fr)	2010-12-01
CA2707418C (fr)	2013-11-19
HK1199731A1 (en)	2015-07-17
AU2008323558A1 (en)	2009-05-22
AU2008323558B2 (en)	2013-10-17
US8710230B2 (en)	2014-04-29
PE20091000A1 (es)	2009-08-14
UY31472A1 (es)	2009-07-17
IL205581A (en)	2014-06-30
PE20130008A1 (es)	2013-02-05
ZA201003283B (en)	2011-03-30
US20140296228A1 (en)	2014-10-02
EA019259B1 (ru)	2014-02-28
EP2220046A4 (fr)	2011-01-05

Publication	Publication Date	Title
TN2010000212A1 (en)	2011-11-11	Inhibitors of human immunodeficiency virus replication
EA201101620A1 (ru)	2012-05-30	Ингибиторы репликации вируса иммунодефицита человека
UY30350A1 (es)	2008-01-02	Inhibidores de la replicacion del virus de la inmunodeficiencia humana
UA104885C2 (uk)	2014-03-25	Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
MY151986A (en)	2014-07-31	Adamantyl diamide derivatives and uses of same
MX2009013349A (es)	2010-01-20	Compuestos quimicos.
EA200870193A1 (ru)	2009-02-27	Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
GEP20146125B (en)	2014-07-25	Aminopyrimidines as syk inhibitors
GEP20186838B (en)	2018-04-10	5-phenoxy-3h-pyrimidin-4-one derivatives and their usage as hiv reverse transcriptase inhibitors
BRPI0917017B8 (pt)	2021-05-25	inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
EA201101397A1 (ru)	2012-05-30	Ингибиторы репликации вируса иммунодефицита человека
MX2010001733A (es)	2010-07-06	Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis.
UY30881A1 (es)	2008-09-02	Derivados de fenotiazina, procedimientos y su uso como productos farmacéuticos
GEP20156368B (en)	2015-09-25	Non-nucleoside reverse transcriptase inhibitors
MX2012003644A (es)	2012-04-30	Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila.
MX2011011733A (es)	2012-02-01	Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos.
MX2012006805A (es)	2012-07-10	Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
CR11423A (es)	2010-06-28	NUEVOS INHIBIDORES DE sEH Y SU USO
UA102858C2 (ru)	2013-08-27	Производные пиридино-пиридинонов, способ их получения и применения в терапии
WO2011143772A9 (fr)	2012-12-20	Inhibiteurs de la réplication du vih
MX2009012222A (es)	2009-12-01	Dihidroquinonas y dihidronaftiridinas como inhibidores de las quinasas c-jun-n-terminales.
JO2682B1 (en)	2013-03-03	Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MA32723B1 (fr)	2011-10-02	Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
EP2343976A4 (fr)	2011-12-14	Procédés d'utilisation de compositions d'aminopyridine à libération prolongée
EA201290229A1 (ru)	2012-08-30	Производные спиролактама и их применение